Nasdaq:US$15.41 (+0.36) | HKEX:HK$24.65 (+1.10) | AIM:£2.23 (-0.04)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors